Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma

Thomas E. Witzig, Pier Luigi Zinzani, Thomas M. Habermann, Joseph Tuscano, Johannes Drach, Radhakrishnan Ramchandren, Sevgi Kalayoglu Besisik, Kenichi Takeshita, Marie Laure Casadebaig Bravo, Lei Zhang, Tommy Fu, Andre Goy

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post-bortezomib). The purpose of this report is to provide longer follow-up on the MCL-001 study (follow-ups were 6.8 [NHL-002], 7.6 [NHL-003], and 52.2 [MCL-001] months). The 206 relapsed MCL patients treated with single-agent lenalidomide (25 mg/day PO, days 1 to 21 every 28-days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow-up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%-29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single-agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.

Original languageEnglish (US)
Pages (from-to)E575-E583
JournalAmerican Journal of Hematology
Volume92
Issue number10
DOIs
StatePublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Witzig, T. E., Luigi Zinzani, P., Habermann, T. M., Tuscano, J., Drach, J., Ramchandren, R., Kalayoglu Besisik, S., Takeshita, K., Casadebaig Bravo, M. L., Zhang, L., Fu, T., & Goy, A. (2017). Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. American Journal of Hematology, 92(10), E575-E583. https://doi.org/10.1002/ajh.24854